Mental health and substance use in the scale-up of HIV prevention

Aaron J. Blashill, Jonathan Lassiter, Johannes M. Wilson, Steven Safren, Jeffrey T. Parsons

Research output: Chapter in Book/Report/Conference proceedingChapter

1 Citation (Scopus)

Abstract

The past several years have witnessed dramatic advances in the potential for effective biomedical HIV prevention interventions. Recent landmark clinical trials, such as CAPRISA 004 and iPrEx, have shown that vaginal microbicides and oral preexposure prophylaxis (PrEP) can reduce the likelihood of HIV infection. Additionally, the results of HIV Prevention Trials Network (HPTN) 052 showed that early initiation of antiretroviral therapy (ART) could also function as a potential biomedical HIV prevention intervention. Nonetheless, many other trials of microbicides and PrEP failed to show a decrease in HIV incidence. Across these trials, it has been hypothesized that poor levels of treatment adherence accounted for the ineffectiveness of the interventions. It is well known that numerous mental health and substance use issues impact adherence to ART, and it is likely that adherence to PrEP and microbicides is similarly affected by these intertwined psychosocial problems. In this chapter, we discuss the impact of mental health and substance use on adherence, HIV transmission risk behavior, PrEP, microbicides, and ART as a secondary prevention strategy. Specifically, we examine how psychosocial syndemics, stigma, risk compensation, intimate partner violence, and the use of various substances (such as alcohol, cocaine, club drugs, methamphetamines) have been important factors in HIV treatment and prevention research to date, and then we present current research that applies these findings to biomedical prevention efforts. Finally, we discuss future research directions for addressing mental health and substance use issues in biomedical prevention interventions.

Original languageEnglish (US)
Title of host publicationBiomedical Advances in HIV Prevention: Social and Behavioral Perspectives
PublisherSpringer New York
Pages139-159
Number of pages21
Volume9781461488453
ISBN (Print)9781461488453, 1461488443, 9781461488446
DOIs
StatePublished - Nov 1 2014
Externally publishedYes

Fingerprint

Mental Health
HIV
Anti-Infective Agents
Therapeutics
Methamphetamine
Risk-Taking
Secondary Prevention
Cocaine
Research
HIV Infections
Alcohols
Clinical Trials
Incidence
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Blashill, A. J., Lassiter, J., Wilson, J. M., Safren, S., & Parsons, J. T. (2014). Mental health and substance use in the scale-up of HIV prevention. In Biomedical Advances in HIV Prevention: Social and Behavioral Perspectives (Vol. 9781461488453, pp. 139-159). Springer New York. https://doi.org/10.1007/978-1-4614-8845-3_7

Mental health and substance use in the scale-up of HIV prevention. / Blashill, Aaron J.; Lassiter, Jonathan; Wilson, Johannes M.; Safren, Steven; Parsons, Jeffrey T.

Biomedical Advances in HIV Prevention: Social and Behavioral Perspectives. Vol. 9781461488453 Springer New York, 2014. p. 139-159.

Research output: Chapter in Book/Report/Conference proceedingChapter

Blashill, AJ, Lassiter, J, Wilson, JM, Safren, S & Parsons, JT 2014, Mental health and substance use in the scale-up of HIV prevention. in Biomedical Advances in HIV Prevention: Social and Behavioral Perspectives. vol. 9781461488453, Springer New York, pp. 139-159. https://doi.org/10.1007/978-1-4614-8845-3_7
Blashill AJ, Lassiter J, Wilson JM, Safren S, Parsons JT. Mental health and substance use in the scale-up of HIV prevention. In Biomedical Advances in HIV Prevention: Social and Behavioral Perspectives. Vol. 9781461488453. Springer New York. 2014. p. 139-159 https://doi.org/10.1007/978-1-4614-8845-3_7
Blashill, Aaron J. ; Lassiter, Jonathan ; Wilson, Johannes M. ; Safren, Steven ; Parsons, Jeffrey T. / Mental health and substance use in the scale-up of HIV prevention. Biomedical Advances in HIV Prevention: Social and Behavioral Perspectives. Vol. 9781461488453 Springer New York, 2014. pp. 139-159
@inbook{bdc11a90ff064e0eb17e26dbc8966bfc,
title = "Mental health and substance use in the scale-up of HIV prevention",
abstract = "The past several years have witnessed dramatic advances in the potential for effective biomedical HIV prevention interventions. Recent landmark clinical trials, such as CAPRISA 004 and iPrEx, have shown that vaginal microbicides and oral preexposure prophylaxis (PrEP) can reduce the likelihood of HIV infection. Additionally, the results of HIV Prevention Trials Network (HPTN) 052 showed that early initiation of antiretroviral therapy (ART) could also function as a potential biomedical HIV prevention intervention. Nonetheless, many other trials of microbicides and PrEP failed to show a decrease in HIV incidence. Across these trials, it has been hypothesized that poor levels of treatment adherence accounted for the ineffectiveness of the interventions. It is well known that numerous mental health and substance use issues impact adherence to ART, and it is likely that adherence to PrEP and microbicides is similarly affected by these intertwined psychosocial problems. In this chapter, we discuss the impact of mental health and substance use on adherence, HIV transmission risk behavior, PrEP, microbicides, and ART as a secondary prevention strategy. Specifically, we examine how psychosocial syndemics, stigma, risk compensation, intimate partner violence, and the use of various substances (such as alcohol, cocaine, club drugs, methamphetamines) have been important factors in HIV treatment and prevention research to date, and then we present current research that applies these findings to biomedical prevention efforts. Finally, we discuss future research directions for addressing mental health and substance use issues in biomedical prevention interventions.",
author = "Blashill, {Aaron J.} and Jonathan Lassiter and Wilson, {Johannes M.} and Steven Safren and Parsons, {Jeffrey T.}",
year = "2014",
month = "11",
day = "1",
doi = "10.1007/978-1-4614-8845-3_7",
language = "English (US)",
isbn = "9781461488453",
volume = "9781461488453",
pages = "139--159",
booktitle = "Biomedical Advances in HIV Prevention: Social and Behavioral Perspectives",
publisher = "Springer New York",

}

TY - CHAP

T1 - Mental health and substance use in the scale-up of HIV prevention

AU - Blashill, Aaron J.

AU - Lassiter, Jonathan

AU - Wilson, Johannes M.

AU - Safren, Steven

AU - Parsons, Jeffrey T.

PY - 2014/11/1

Y1 - 2014/11/1

N2 - The past several years have witnessed dramatic advances in the potential for effective biomedical HIV prevention interventions. Recent landmark clinical trials, such as CAPRISA 004 and iPrEx, have shown that vaginal microbicides and oral preexposure prophylaxis (PrEP) can reduce the likelihood of HIV infection. Additionally, the results of HIV Prevention Trials Network (HPTN) 052 showed that early initiation of antiretroviral therapy (ART) could also function as a potential biomedical HIV prevention intervention. Nonetheless, many other trials of microbicides and PrEP failed to show a decrease in HIV incidence. Across these trials, it has been hypothesized that poor levels of treatment adherence accounted for the ineffectiveness of the interventions. It is well known that numerous mental health and substance use issues impact adherence to ART, and it is likely that adherence to PrEP and microbicides is similarly affected by these intertwined psychosocial problems. In this chapter, we discuss the impact of mental health and substance use on adherence, HIV transmission risk behavior, PrEP, microbicides, and ART as a secondary prevention strategy. Specifically, we examine how psychosocial syndemics, stigma, risk compensation, intimate partner violence, and the use of various substances (such as alcohol, cocaine, club drugs, methamphetamines) have been important factors in HIV treatment and prevention research to date, and then we present current research that applies these findings to biomedical prevention efforts. Finally, we discuss future research directions for addressing mental health and substance use issues in biomedical prevention interventions.

AB - The past several years have witnessed dramatic advances in the potential for effective biomedical HIV prevention interventions. Recent landmark clinical trials, such as CAPRISA 004 and iPrEx, have shown that vaginal microbicides and oral preexposure prophylaxis (PrEP) can reduce the likelihood of HIV infection. Additionally, the results of HIV Prevention Trials Network (HPTN) 052 showed that early initiation of antiretroviral therapy (ART) could also function as a potential biomedical HIV prevention intervention. Nonetheless, many other trials of microbicides and PrEP failed to show a decrease in HIV incidence. Across these trials, it has been hypothesized that poor levels of treatment adherence accounted for the ineffectiveness of the interventions. It is well known that numerous mental health and substance use issues impact adherence to ART, and it is likely that adherence to PrEP and microbicides is similarly affected by these intertwined psychosocial problems. In this chapter, we discuss the impact of mental health and substance use on adherence, HIV transmission risk behavior, PrEP, microbicides, and ART as a secondary prevention strategy. Specifically, we examine how psychosocial syndemics, stigma, risk compensation, intimate partner violence, and the use of various substances (such as alcohol, cocaine, club drugs, methamphetamines) have been important factors in HIV treatment and prevention research to date, and then we present current research that applies these findings to biomedical prevention efforts. Finally, we discuss future research directions for addressing mental health and substance use issues in biomedical prevention interventions.

UR - http://www.scopus.com/inward/record.url?scp=84929932874&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84929932874&partnerID=8YFLogxK

U2 - 10.1007/978-1-4614-8845-3_7

DO - 10.1007/978-1-4614-8845-3_7

M3 - Chapter

SN - 9781461488453

SN - 1461488443

SN - 9781461488446

VL - 9781461488453

SP - 139

EP - 159

BT - Biomedical Advances in HIV Prevention: Social and Behavioral Perspectives

PB - Springer New York

ER -